Literature DB >> 10026069

Questions about palivizumab (Synagis)

S L Lee, J L Robinson.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10026069

Source DB:  PubMed          Journal:  Pediatrics        ISSN： 0031-4005            Impact factor:   7.124


× No keyword cloud information.
  2 in total

1.  Net cost of palivizumab for respiratory syncytial virus prophylaxis during the 1998/99 season in northern Alberta.

Authors:  S L Lee; P Etches; J L Robinson
Journal:  Paediatr Child Health       Date:  2001-10       Impact factor: 2.253

2.  Prophylaxis of respiratory syncytial virus in Canada in 2003.

Authors:  Joan L Robinson; Bonita E Lee
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.